Moreover, endocrine pathways are also potential targets for pharmacological treatment, as shown by the estrogen-receptor blocker raloxifene; that is well-known for its impact on the treatment of osteoporosis and some types of cancer. The gene discussed is ESR1; the disease is cancer.